Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

The Q3 recap for nephrology spotlights key FDA decisions, new KDIGO IgA nephropathy guidelines, and other top renal news and research.

Q3 2025 Recap: Nephrology News and Updates

An audio recap of the top 5 stories in healthcare news from the week of 9/5-9/13.

HCPLive 5 Stories in Under 5: Week of 09/07

Upon further review of the sNDA, the Agency indicated an advisory committee for sparsentan in FSGS is no longer needed. 

FDA Removes Sparsentan (Filspari) Advisory Committee Meeting for FSGS sNDA

The Q2 recap for nephrology spotlights key FDA decisions and top coverage from the 62nd European Renal Association Congress.

Q2 2025 Recap: Nephrology News and Updates

A study presented at ERA 2025 validates the use of proteinuria as a surrogate endpoint for FSGS clinical trials. 

RaDaR Validation Confirms PARASOL Findings on FSGS Surrogate Endpoint, with Daniel Gale, PhD, MB BChir

With the sNDA acceptance, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026.

FDA Accepts Sparsentan (Filspari) sNDA for Focal Segmental Glomerulosclerosis

Norouzi discusses recent advancements in IgAN therapeutics and looks ahead to a potential first FDA-approved FSGS treatment.

The Evolving IgAN Treatment Landscape and Advances in FSGS, with Sayna Norouzi, MD

Tumlin reviews findings from a posthoc analysis of DUPLEX demonstrating sparsentan’s impact on partial remission, complete remission, and kidney failure.

Sparsentan and Progression to Kidney Failure in FSGS, with James Tumlin, MD

The submission is supported by results from the phase 3 DUPLEX Study and the phase 2 DUET Study in adult and pediatric patients with FSGS.

Travere Therapeutics Submits sNDA for Sparsentan (Filspari) in FSGS

An approval for sparsentan in focal segmental glomerulosclerosis would mark the second rare kidney disease approval for the agent.

Travere Therapeutics Plans FSGS Submission for Sparsentan

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 